A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
Journal of Korean Medical Science
;
: 598-602, 2005.
Article
in English
| WPRIM
| ID: wpr-147620
ABSTRACT
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3 mg/m2 twice weekly for 2 week in a 3-week cycle). Seven patients were enrolled. The median age of patients was 59 yr. All patients previously received VAD (vincristine, doxorubicin and dexamethasone) and thalidomide chemotherapy. Three patients previously received alkylator-containing chemotherapy and 4 patients, autologous stem cell transplantation. Bortezomib monotherapy resulted in 3 partial remissions (43%), 3 no changes (43%) and 1 progressive disease (14%). One patient who had no response to bortezomib monotherapy experienced partial remission after addition of dexamethasone to bortezomib. The most common serious toxicity was thrombocytopenia (grade 3/4, 10 of 20 cycles (50%)) and grade 3 peripheral neuropathy was developed in 2 of 20 cycles (10%). Drug-related adverse event led to discontinuation of bortezomib in 1 patient. There was no treatment related mortality. Overall, bortezomib seems to be effective and feasible. Conduction of larger clinical studies on Korean patients is necessary to characterize clinical efficacy and safety of bortezomib more precisely.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pyrazines
/
Thrombocytopenia
/
Time Factors
/
Boronic Acids
/
Dexamethasone
/
Antineoplastic Combined Chemotherapy Protocols
/
Survival Analysis
/
Pilot Projects
/
Disease Progression
/
Drug Resistance, Neoplasm
Limits:
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS